Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
94
resultados
Última actualización
04/02/2026 [07:12:00]
Resumen de: NZ791834A
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Resumen de: US20260028673A1
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.
Resumen de: US20260029316A1
An immunochromatographic method for a trace amount of an antigen or an antibody such as SARS-COV-2 including use of saliva, enabling highly sensitive immunochromatographic antigen or antibody detection even when the saliva is used. A method for pretreatment of a specimen for an immunochromatographic test, including passing the saliva through a porous member capable of supporting a viscous component in the saliva to remove the viscous component, passing the liquid that has passed through the porous member through a filter having a hole diameter of from 0.1 μm to 10 μm, and concentrating an antigen or an antibody in the liquid that has passed through the filter.
Resumen de: WO2026023869A1
The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.
Resumen de: US20260028685A1
In one aspect, the inventive technology relates to improved systems, methods, and compositions for a novel saliva stabilization solution for use in nucleic acid amplification reactions, and in particular embodiment its use in the detection of pathogen nucleic acids, such as SARS-CoV-2 (COVID-19).
Resumen de: US20260028644A1
Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.
Resumen de: WO2026023870A1
The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.
Resumen de: AU2024335376A1
The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.
Resumen de: WO2026021236A1
Provided are a polypeptide capable of inhibiting a MERS-like coronavirus infection, and a use thereof. On the basis of a membrane fusion invasion feature mediated by an S2 subunit of a MjHKU4r-CoV coronavirus S protein, a group of polypeptides are invented by using the HR1 functional domain of the protein as a target. The polypeptides can efficiently inhibit the membrane fusion invasion process of a MERS-like coronavirus MjHKU4r-CoV. By competitively binding to a viral HR1 functional domain, these polypeptides inhibit the formation of a viral 6-helix bundle (6-HB) fusion core, thereby efficiently blocking the process of the coronavirus MjHKU4r-CoV invading a target cell. The present invention can provide an efficient preventive and therapeutic candidate drug for prevention and treatment of the MERS-like coronavirus MjHKU4r-CoV having potential high pathogenicity and cross-species transmission.
Resumen de: EP4684778A1
Provided is a pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and an auxiliary material. The auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant. The pharmaceutical composition has the feasibility of preparation process, excellent properties of preparations, good stability and good dissolution, and meets the pharmaceutical standards.
Resumen de: WO2026018060A1
The present invention in general relates to a pharmaceutical formulation, specifically a dry powder inhalation formulation for treatment of Corona virus disease-19 (COVID-19). The formulation comprises of combination of an antiviral and a corticosteroid. The invention further describes the method of preparation of the dry powder inhalation formulation.
Resumen de: WO2026018922A1
The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and/or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and/or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.
Resumen de: WO2026019338A1
The invention relates to organic chemistry, pharmacology and medicine and concerns novel antiviral peptides. The claimed peptides are characterized by a high level of antiviral activity and show promise for use in the treatment of infectious diseases caused by a viral infection, inter alia, diseases caused by SARS-CoV-2 such as, for example, a simple infection (such as a fever, a cough and/or a sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock and, in particular, COVID-19.
Resumen de: NL2039943A
The invention relates to the technical field of biopharmaceuticals, in particular to an application of a dual-target polypeptide for simultaneously inhibiting the activities of Furin and Mpro in the prevention and treatment of COVID-19. In order to provide a polypeptide with inhibitory activity on Furin and Mpro at the same time, the 42nd, 45th and 46th amino acids of Eglin C are mutated at site to obtain Eglin C mutants. According to the research of the invention, it is found that the Eglin C mutant can significantly inhibit the activities of Furin protease and Mpro protease. The Eglin C mutant provides a new research direction and idea for the development of polypeptide drugs for preventing and treating Covid-19.
Resumen de: US20260021204A1
The present disclosure relates to anti-SARS-COV-1 and anti-SARS-COV-2 activatable RNase guide sequences and methods of use for screening, treating, and/or preventing SARS infections and/or COVID-related diseases.
Resumen de: WO2026017760A1
5 A composition in oral dosage form comprises tryptophan or at least one tryptophan intermediate, and at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and/or (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. The composition may include a cohort of bacteria 10 including at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and at least one bacterium that (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. Typically, the cohort of bacteria is capable of producing the immunomodulatory indole derivatives indole-3-lactic acid (ILA), 15 indole-3-propionic acid (IPA) and indole acrylic acid (IA). The composition finds utility in inhibition or prevention of immune-mediated inflammatory damage in subjects with an immune-mediated infectious or non-infectious disease, and in particular can prevent a severe inflammatory response or incidence of Long Covid in SARS-CoV-19 subjects. 20 (Figure 16)
Resumen de: US20260022379A1
Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.
Resumen de: WO2026016695A1
Disclosed is use of coronavirus SL5s as targets in the preparation of a drug for preventing and treating coronavirus infection. The drug target coronavirus SL5s described in the present invention are the stem-loops 5 of the 5'UTR regions of coronaviruses, which participate in regulating viral mRNA translation. Further disclosed is an inhibitor of the SL5s of 7 human infectious coronaviruses, i.e., an antisense oligonucleotide specifically targeting the SL5s for inhibiting coronavirus infection. Experiments have demonstrated that the application of the antisense oligonucleotide specifically targeting the coronavirus SL5s in vitro can significantly inhibit the translation levels of the coronavirus mRNAs. The coronavirus SL5s described in the present invention can be used as drug targets to screen for candidate drugs for inhibiting coronavirus mRNA translation, showing great significance for the development of anti-coronavirus drugs and the prevention and treatment of coronaviruses in the future.
Resumen de: AU2025283673A1
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of SARS-CoV-2 nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits and related methods for preparing aqueous reaction mixtures from dried formulations. ec e c
Resumen de: AU2024308469A1
Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).
Resumen de: AU2024303786A1
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Resumen de: AU2024280139A1
The present invention relates to an immunogenic composition comprising a recombinant peptide and protein, wherein the recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, a chimeric antigen and immunogen of an S protein peptide or a fragment, variant or mutant sequence thereof of SARS-CoV-2 Hu-1, SARS-CoV-2 Omicron (BA.5 and/or XBB.1.5) variant, and/or other variants. The immunogenic composition comprises a secreted fusion protein, which comprises a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked, by means of in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The immunogenic composition can be used for generating an immune response, and can be used in a vaccine composition. Further provided are methods for producing a recombinant peptide and protein, methods for prevention, treatment and/or diagnosis, and a related kit.
Resumen de: US20260022111A1
Provided herein are compounds having a structure of formula (I) or formula (II):or a pharmaceutically acceptable salt, solvate, or hydrate thereof, useful in treating or preventing coronavirus infection. In some embodiments, the coronavirus infection is COVID-19 (SARS-COV-19). Also provided are compositions comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus infection.
Resumen de: EP4682160A1
The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.
Nº publicación: EP4682890A2 21/01/2026
Solicitante:
BAIDU USA LLC [US]
Baidu USA LLC
Resumen de: EP4682890A2
A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.
BOPI
Sede Electrónica
